Koga Yuhki, Kumagai Masaaki, Takimoto Tetsuya, Mimaya Jun-Ichi, Nakazawa Atsuko, Horibe Keizo, Kobayashi Ryoji, Tsurusawa Masahito, Inada Hiroko, Mori Tetsuya
Japanese Pediatric Leukemia/Lymphoma Study Group.
Rinsho Ketsueki. 2012 Apr;53(4):443-9.
Hodgkin lymphoma is an easily curable malignancy in the pediatric age group and is less frequently observed in Japan. No study with a large sample size of Japanese patients has been conducted. From 1985 to 2000, 157 Japanese patients with Hodgkin lymphoma were retrospectively analyzed based on their clinical characteristics, treatment regimen, and treatment outcome by 4 pediatiric cancer study groups. There were 107 male and 50 female patients with a median age of 10 years 1 month (range: 1 year 8 months to 17 years 8 months). Clinical stage I lymphoma was observed in 37 patients, stage II in 62, stage III in 40, and stage IV in 18. Fifty patients presented with B symptoms (32%). Most patients (n=125, 82%) received more than 6 courses of combination chemotherapy mainly comprising cyclophosphamide, vincristine, procarbazine, prednisolone (COPP), doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). The 5-year overall and event-free survival rates were 81.5% and 94.8%, respectively. High-risk disease and age (>10 years) were considered to be poor prognostic factors.
霍奇金淋巴瘤在儿童年龄组中是一种易于治愈的恶性肿瘤，在日本较少见。尚未有针对大量日本患者样本的研究。1985年至2000年期间，4个儿科癌症研究小组对157例日本霍奇金淋巴瘤患者的临床特征、治疗方案及治疗结果进行了回顾性分析。患者中男性107例，女性50例，中位年龄为10岁1个月（范围：1岁8个月至17岁8个月）。37例患者为临床I期淋巴瘤，62例为II期，40例为III期，18例为IV期。50例患者出现B症状（32%）。大多数患者（n = 125，82%）接受了6个以上疗程的联合化疗，主要包括环磷酰胺、长春新碱、丙卡巴肼、泼尼松龙（COPP）、阿霉素、博来霉素、长春花碱和达卡巴嗪（ABVD）。5年总生存率和无事件生存率分别为81.5%和94.8%。高危疾病和年龄（>10岁）被认为是不良预后因素。
